Aurinia Closes US$191.7 Million Public Offering of Common Shares & Full Exercise of Underwriters’ Option to Purchase Additi...
December 12 2019 - 9:26AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia”
or the “Company”), a late-stage clinical biopharmaceutical company
focused on advancing voclosporin in multiple indications, today
announced the closing of its previously announced underwritten
public offering of 12,782,439 common shares, including 1,667,274
common shares pursuant to the full exercise of the underwriters’
option to purchase additional common shares (the “Offering”). The
shares were sold at a public offering price of US$15.00 per share.
The gross offering proceeds to the Company from this Offering are
approximately US$191.7 million, before deducting underwriting
discounts and commissions and other estimated offering
expenses.
Jefferies LLC and SVB Leerink LLC acted as joint book-running
managers for the Offering. H.C. Wainwright & Co. LLC,
Oppenheimer & Co. Inc., and Bloom Burton Securities Inc. acted
as co-managers for the Offering.
For the purposes of the TSX approval, the Company relied on the
exemption set forth in Section 602.1 of the TSX Company Manual,
which provides that the TSX will not apply its standards to certain
transactions involving eligible inter-listed issuers on a
recognized exchange, such as NASDAQ.
The Company intends to use the net proceeds of the Offering for
pre-commercialization and launch activities, as well as working
capital and general corporate purposes.
The Offering was made pursuant to a U.S. registration statement
on Form F-10, declared effective by the United States Securities
and Exchange Commission (the “SEC”) on March 29, 2018 (the
“Registration Statement”), and the Company’s existing Canadian
short form base shelf prospectus (the “Base Shelf Prospectus”)
dated March 26, 2018. The prospectus supplements relating to the
Offering (together with the Base Shelf Prospectus and the
Registration Statement, the “Offering Documents”) have been filed
with the securities commissions in the provinces of British
Columbia, Alberta and Ontario in Canada, and with the SEC in the
United States. The Offering Documents contain important detailed
information about the securities being offered. Before you invest,
you should read the Offering Documents and the other documents the
Company has filed for more complete information about the Company
and the Offering. Copies of the Offering Documents are available
for free by visiting the Company’s profiles on the SEDAR website
maintained by the Canadian Securities Administrators at
www.sedar.com or the SEC’s website at www.sec.gov, as applicable.
Alternatively, copies of the prospectus supplement are available
upon request by contacting Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022; by phone at (877) 821-7388; or by e-mail at
Prospectus_Department@Jefferies.com; or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at 1-800-808-7525, ext. 6132, or by email at
syndicate@svbleerink.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, nor will there be any
sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
ABOUT AURINIA
Aurinia Pharmaceuticals is a late clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are impacted
by serious diseases with a high unmet medical need. The Company is
currently developing an investigational drug, for the treatment of
lupus nephritis, focal segmental glomerulosclerosis and dry eye
syndrome. The Company’s head office is in Victoria, British
Columbia and focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191212005455/en/
Investors & Media: Glenn Schulman, PharmD, MPH SVP,
Corporate Communications & IR gschulman@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024